Why the study?
Does levosimendan improve hemodynamics in a patient with catecholamine-resistant cardiogenic shock due to neurogenic stress cardiomyopathy?
Does levosimendan improve hemodynamics in a patient with catecholamine-resistant cardiogenic shock due to neurogenic stress cardiomyopathy?
Levosimendan may be an effective treatment for catecholamine-resistant cardiogenic shock due to neurogenic stress cardiomyopathy following subarachnoid hemorrhage.
Answers are grounded in this paper and cite their sources.
May support levosimendan in monitored, catecholamine-resistant NSC shock; hypothesis-generating pending controlled trials.
We present a case of cardiogenic shock due to neurogenic stress cardiomyopathy (NSC) in a patient with nontraumatic subarachnoid hemorrhage caused by a ruptured aneurysm of the right pericallosal artery. Due to the catecholamine-resistant shock, levosimendan was administered under advanced hemodynamic control, including transpulmonary thermodilution and echocardiography. This resulted in an improved cardiac contractility and reduced demand for catecholamines. Full stabilization of hemodynamic parameters was achieved by day 5. In the discussion section we reviewed available published case reports of using levosimendan in stress cardiomyopathy treatment.
No takes yet. Share an insight, caveat, or question.
Полупан et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: